Merck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, made a significant announcement today at the EUROGIN 2024 HPV Congress. The company revealed its intentions to commence clinical development of a groundbreaking investigational multi-valent HPV vaccine…